Metformin Therapy Center

In patients with stage 3 kidney disease, metformin use may be safe and may reduce the risk of mortality and cardiovascular events.

FDA label change warns of increased risk of lactic acidosis in patients with severe renal dysfunction.

Study investigates preservation or improvement of B-cell function using metformin with or without short-term insulin.

Restoring Insulin Secretion (RISE) Pediatric Medication Study shows that youth have markedly reduced insulin sensitivity and respond differently to medications.

Use of metformin may decrease chances of developing gastric cancer in patients with T2D.

Study confirms recent guideline changes on metformin use in moderate-to-severe chronic kidney disease.

Long-term impact of intrauterine exposure to medication on the offspring remains unclear.

Patients who skipped initial treatment with metformin and were instead started on second-line antihyperglycemic medication more likely to need dual therapy or insulin to control T2.

Determining which patients benefit most from lifestyle, metformin interventions may improve individualized care decisions.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.